Lifestyle Diseases and the Hair Growth Cycle: A Multidisciplinary Approach Using Nourkrin with Marilex, a Proteoglycan Replacement Therapy, for Anagen Induction and Maintenance

The 2017 study found a link between androgenetic alopecia (AGA), a common hair loss condition, and lifestyle diseases such as cardiovascular disease and metabolic syndrome. Patients with AGA often had higher rates of these diseases. The study emphasized the need to treat hair loss caused by metabolic syndrome to prevent further hair loss. It suggested Nourkrin® with Marilex®, a proteoglycan replacement therapy, as an effective treatment, as it increased hair count by up to 35.7% over six months in a trial. The study concluded that early onset AGA and female pattern hair loss are risk factors for metabolic syndrome, and treatment should begin as soon as hair growth disruption is noticed. The document also stressed the importance of considering potential interactions with ongoing medical treatments when choosing a hair loss treatment.